Stephens & Co. Maintains Overweight on BioLife Solns, Raises Price Target to $29
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Jacob Johnson maintains an Overweight rating on BioLife Solns (NASDAQ:BLFS) and raises the price target from $27 to $29.
July 17, 2023 | 3:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stephens & Co. maintains an Overweight rating on BioLife Solns and raises the price target from $27 to $29, which could positively impact the stock price.
The Overweight rating maintained by Stephens & Co. indicates that they believe BioLife Solns will outperform the market. The increase in the price target from $27 to $29 suggests that they expect the stock price to rise, which could attract investors and drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100